We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Quince Therapeutics Inc | NASDAQ:QNCX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.9851 | 0.90 | 0.9851 | 0 | 09:00:00 |
UNITED STATES | ||
SECURITIES AND EXCHANGE COMMISSION | ||
Washington, D.C. 20549 | ||
SCHEDULE 13G | ||
(Rule 13d-102) | ||
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT | ||
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED | ||
PURSUANT TO RULE 13d-2(b) | ||
(Amendment No. 3) 1
|
||
Cortexyme, Inc. | ||
(Name of Issuer) | ||
Common Stock, $0.001 par value | ||
(Title of Class of Securities) | ||
22053A107 | ||
(CUSIP Number) | ||
December 31, 2021 | ||
(Date of Event Which Requires Filing of this Statement) |
1. |
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)
Pfizer Inc. 13-5315170
|
|||||||||||||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) [ ]
(b) [ ]
|
||||||||||||
3. | SEC USE ONLY | |||||||||||||
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
|||||||||||||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5. |
SOLE VOTING POWER -0-
|
||||||||||||
6. |
SHARED VOTING POWER 600,000 shares of Common Stock, $0.001 par value per share (“Common Stock”) directly held by PF Equity Holdings 4 B.V., a controlled affiliate of Pfizer Inc.
|
|||||||||||||
7. | SOLE DISPOSITIVE POWER -0- | |||||||||||||
8. | SHARED DISPOSITIVE POWER 600,000 shares of Common Stock held directly by PF Equity Holdings 4 B.V., a controlled affiliate of Pfizer Inc. | |||||||||||||
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON 600,000* |
|||||||||||||
10. |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
[ ] |
||||||||||||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.01%** | |||||||||||||
12. | TYPE OF REPORTING PERSON CO |
1. |
NAME OF REPORTING PERSON PF Equity Holdings 4 B.V.
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY) 98-1625216
|
|||||||||||||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) [ ]
(b) [ ]
|
||||||||||||
3. | SEC USE ONLY | |||||||||||||
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Netherlands
|
|||||||||||||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5. | SOLE VOTING POWER -0- | ||||||||||||
6. | SHARED VOTING POWER 600,000 shares of Common Stock | |||||||||||||
7. | SOLE DISPOSITIVE POWER -0- | |||||||||||||
8. | SHARED DISPOSITIVE POWER 600,000 Shares of Common Stock | |||||||||||||
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON 600,000 shares of Common Stock held directly by PF Equity Holdings 4 B.V., a controlled affiliate of Pfizer Inc. formed to hold certain assets owned or controlled by Pfizer or its direct or indirect subsidiaries. |
|||||||||||||
10. |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
[ ] |
||||||||||||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.01%** | |||||||||||||
12. | TYPE OF REPORTING PERSON OO |
ITEM 1(a) | NAME OF ISSUER: Cortexyme, Inc. (the “Issuer”). | ||||
ITEM 1(b) | ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: | ||||
269 Grand Avenue, South San Francisco, CA 94080 | |||||
ITEM 2(a) | NAME OF PERSON FILING: | ||||
Pfizer Inc. (“Pfizer”)
PF Equity Holdings 4 B.V. (“PEH4”)
PEH4 is a wholly-owned subsidiary of Pfizer formed to hold certain assets owned or controlled by Pfizer or its direct or indirect subsidiaries. The Joint Filing Agreement between Pfizer and PEH4 is filed herewith as Exhibit 99.1.
|
|||||
ITEM 2(b) | ADDRESS OF PRINCIPAL BUSINESS OFFICE: | ||||
Pfizer: 235 East 42nd Street, New York, NY 10017
|
|||||
PEH4: Rivium Westlaan 142, 2909 LD, Capelle aan den IJssel, Netherlands | |||||
ITEM 2(c) | CITIZENSHIP: | ||||
Pfizer: Delaware | |||||
PEH4: Netherlands | |||||
ITEM 2(d) | TITLE OF CLASS OF SECURITIES: | ||||
Common Stock, $0.001 par value | |||||
ITEM 2(e) | CUSIP NUMBER: 22053A107 | ||||
ITEM 3 | STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C): | ||||
Not applicable. | |||||
ITEM 4 | OWNERSHIP: | ||||||||||||||||||||||
The information requested in this item is incorporated herein by reference to rows 5 through 11 of the respective cover pages of Pfizer and PEH4 to this Schedule 13G. | |||||||||||||||||||||||
ITEM 5 | OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: | ||||||||||||||||||||||
| X | | |||||||||||||||||||||||
ITEM 6 | OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: | ||||||||||||||||||||||
Not applicable. | |||||||||||||||||||||||
ITEM 7 | IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY: | ||||||||||||||||||||||
Not applicable. | |||||||||||||||||||||||
ITEM 8 | IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: | ||||||||||||||||||||||
Not applicable. | |||||||||||||||||||||||
ITEM 9 | NOTICE OF DISSOLUTION OF GROUP: | ||||||||||||||||||||||
Not applicable. | |||||||||||||||||||||||
ITEM 10 | CERTIFICATION: | ||||||||||||||||||||||
99.1 | Joint Filing Agreement, dated as of February 11, 2022, by and between Pfizer and PEH4. |
PFIZER INC. | ||||||||
By: | /s/ Susan Grant | |||||||
Name: | Susan Grant | |||||||
Title: | Assistant Secretary | |||||||
PF EQUITY HOLDINGS 4 B.V. | ||||||||
By: | /s/ Susan Grant | |||||||
Name: | Susan Grant | |||||||
Title: | Attorney-in-fact |
1 Year Quince Therapeutics Chart |
1 Month Quince Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions